Key Insights

Highlights

Treatment Research

1 treatments under study, led by Nonavalent Hpv Vaccine 9vhpvgardasil9

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05334706Phase 4Recruiting

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

Showing all 1 trials

Research Network

Common Treatments

  • Nonavalent Hpv Vaccine 9vhpvgardasil91

Active Sponsors

  • Catalan Institute of Health1
  • Miquel Angel Pavon Ribas1
  • Hospital del Mar1

Top Investigators

  • Miquel Àngel Pavón Ribas, PhD1

    Cancer Epidemiology Research Program (PREC), Catalan Institute of Oncology (ICO-Hospitalet)/Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.

  • Francesc Xavier Bosch José, PhD - MD1

    Cancer Epidemiology Research Program (PREC), Catalan Institute of Oncology (ICO-Hospitalet)/Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.

Related Conditions

  • Cervical Intraepithelial Neoplasia Grade I Ii Iii Cin Iiiiii1
  • Highrisk Hpv1
  • Human Papillomavirus Hpv Infections1

Activity Timeline